What does HG Pharma do?

HG Pharma is registered with the CBE as active in: Activiteiten van holdings. Private Limited, started on 28 December 2010, 1 establishment.

What is the address of HG Pharma?

The registered office of HG Pharma is located at Avenue des Fauvettes 23, 1341 Ottignies-Louvain-la-Neuve.

Is HG Pharma still active?

Yes. According to the CBE (31 October 2026) HG Pharma is active, legal situation “Normale toestand”, started on 28 December 2010.

Is HG Pharma registered on Peppol?

Yes, HG Pharma is registered on the Peppol network with ID 0208:0832287120.

What is the enterprise number of HG Pharma?

The enterprise number of HG Pharma is BE0832287120.

When was HG Pharma founded?

HG Pharma was founded on 28 December 2010.

Who are the directors of HG Pharma?

According to the 2025 annual accounts, the directors of HG Pharma are: HELENE GEERAERTS, GILLES SMITS.

Is HG Pharma a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 28 December 2010; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did HG Pharma make in 2025?

HG Pharma posted a profit after taxes of € 144,349 in financial year 2025.

What is the revenue of HG Pharma?

As a small company, HG Pharma is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 367,522.

How many employees does HG Pharma have?

According to the 2025 annual accounts, HG Pharma has 0.9 full-time equivalents (FTE).

HG Pharma (Private Limited) - Ottignies-Louvain-la-Neuve

Dossier HG Pharma, printed on 31 October 2026 from databakkes.be/en/0832287120/hg-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

HG Pharma from Ottignies-Louvain-la-Neuve, company number BE0832287120, closed financial year 2025 with a result of € 144,349 after tax. For that financial year HG Pharma recorded a gross margin of € 367,522 and equity of € 427,572. Compared with financial year 2024, the result moved from € 96,520 to € 144,349. Profitable, and profit is growing. The company holds a healthy buffer. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on April 27, 2026.

What it is worth Healthy

€ 427,572

▼ 10% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 144,349

▲ 50% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 30,149

▼ 60% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 190,000 paid out

More than the year’s profit went to the shareholders; reserves fell.

People and assets in 2025

Full-time equivalents

0.9

▲ 0.1 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 79,135

▲ 26% vs 2024

Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 23,569

▼ 34% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 11 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 1.6 million

▲ € 1.4 million vs 2024

€ 144,274 is repaid this year. At this pace the long-term loan is gone in ≈ 11 years.

Owed to suppliers

€ 7,881

▲ € 7,493 vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 61,061

▲ 132% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 139,743 Gross margin 2022: € 139,743 First fiscal year in the series	€ 199,476 Gross margin 2023: € 199,476 ▲ 43% vs 2022 (€ 139,743) Favourable step	€ 227,717 Gross margin 2024: € 227,717 ▲ 14% vs 2023 (€ 199,476) Favourable step	€ 367,522 Gross margin 2025: € 367,522 ▲ 61% vs 2024 (€ 227,717) Favourable step	▲ 61%
Profit after taxes	€ 123,083 Profit after taxes 2022: € 123,083 First fiscal year in the series	€ 39,809 Profit after taxes 2023: € 39,809 ▼ 68% vs 2022 (€ 123,083) Unfavourable step	€ 96,520 Profit after taxes 2024: € 96,520 ▲ 142% vs 2023 (€ 39,809) Favourable step	€ 144,349 Profit after taxes 2025: € 144,349 ▲ 50% vs 2024 (€ 96,520) Favourable step	▲ 50%
Equity	€ 366,894 Equity 2022: € 366,894 First fiscal year in the series	€ 388,703 Equity 2023: € 388,703 ▲ 6% vs 2022 (€ 366,894) Favourable step	€ 473,223 Equity 2024: € 473,223 ▲ 22% vs 2023 (€ 388,703) Favourable step	€ 427,572 Equity 2025: € 427,572 ▼ 10% vs 2024 (€ 473,223) Unfavourable step	▼ 10%
Total debts	€ 2,205,518 Total debts 2022: € 2,205,518 First fiscal year in the series	€ 2,191,596 Total debts 2023: € 2,191,596 ▼ 1% vs 2022 (€ 2,205,518) Favourable step	€ 2,073,509 Total debts 2024: € 2,073,509 ▼ 5% vs 2023 (€ 2,191,596) Favourable step	€ 4,439,571 Total debts 2025: € 4,439,571 ▲ 114% vs 2024 (€ 2,073,509) Unfavourable step	▲ 114%
Cash	€ 21,111 Cash 2022: € 21,111 First fiscal year in the series	€ 25,428 Cash 2023: € 25,428 ▲ 20% vs 2022 (€ 21,111) Favourable step	€ 75,547 Cash 2024: € 75,547 ▲ 197% vs 2023 (€ 25,428) Favourable step	€ 30,149 Cash 2025: € 30,149 ▼ 60% vs 2024 (€ 75,547) Unfavourable step	▼ 60%
Retained profit	€ 360,694 Retained profit 2022: € 360,694 First fiscal year in the series	€ 382,503 Retained profit 2023: € 382,503 ▲ 6% vs 2022 (€ 360,694) Favourable step	€ 467,023 Retained profit 2024: € 467,023 ▲ 22% vs 2023 (€ 382,503) Favourable step	€ 421,372 Retained profit 2025: € 421,372 ▼ 10% vs 2024 (€ 467,023) Unfavourable step	▼ 10%
Dividend	€ 50,000 Dividend 2022: € 50,000 First fiscal year in the series	€ 18,000 Dividend 2023: € 18,000 ▼ 64% vs 2022 (€ 50,000) Unchanged	€ 12,000 Dividend 2024: € 12,000 ▼ 33% vs 2023 (€ 18,000) Unchanged	€ 190,000 Dividend 2025: € 190,000 ▲ € 178,000 vs 2024 (€ 12,000) Unchanged	▲ € 178,000
Bank debt	€ 165,771 Bank debt 2022: € 165,771 First fiscal year in the series	€ 201,664 Bank debt 2023: € 201,664 ▲ 22% vs 2022 (€ 165,771) Unfavourable step	€ 166,935 Bank debt 2024: € 166,935 ▼ 17% vs 2023 (€ 201,664) Favourable step	€ 1,590,235 Bank debt 2025: € 1,590,235 ▲ € 1.4 million vs 2024 (€ 166,935) Unfavourable step	▲ € 1.4 million
Balance sheet total	€ 2,572,411 Balance sheet total 2022: € 2,572,411 First fiscal year in the series	€ 2,580,300 Balance sheet total 2023: € 2,580,300 Unchanged (€ 2,572,411) Unchanged	€ 2,546,732 Balance sheet total 2024: € 2,546,732 ▼ 1% vs 2023 (€ 2,580,300) Unchanged	€ 4,867,143 Balance sheet total 2025: € 4,867,143 ▲ 91% vs 2024 (€ 2,546,732) Unchanged	▲ 91%
Employees (FTE)	0.1 Employees (FTE) 2022: 0.1 First fiscal year in the series	0.8 Employees (FTE) 2023: 0.8 ▲ 0.7 vs 2022 (0.1) Unchanged	0.8 Employees (FTE) 2024: 0.8 Unchanged (0.8) Unchanged	0.9 Employees (FTE) 2025: 0.9 ▲ 0.1 vs 2024 (0.8) Unchanged	▲ 0.1

Key figures of HG Pharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to HG Pharma?

What happened at HG Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Apr 27, 2026 New annual accounts for financial year 2025: profit of € 144,349 (▲ 50% vs 2024). Source: NBB ↗
Dec 28, 2010 New establishment in Wavre. KBO
2010 HELENE GEERAERTS became a director. NBB
2010 GILLES SMITS became a director. NBB
Dec 28, 2010 Start of the company according to the CBE. KBO

In short

From € 123,083 profit in 2022 to € 144,349 profit in 2025.

Paid € 178,602 in corporate taxes since 2022.

Best year ever: 2025, with € 144,349 profit.

Paid out € 270,000 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

HELENE GEERAERTS

GILLES SMITS

HG Pharma

SMITS SA 100%

PHARMACIE SMITS EUROPE 100%

PHARMA SMITS BASSE WAVRE 99%

Behind HG Pharma are HELENE GEERAERTS and GILLES SMITS. It owns 100% of SMITS SA, 100% of PHARMACIE SMITS EUROPE and 99% of PHARMA SMITS BASSE WAVRE itself.

Directors

According to the 2025 annual accounts

HELENE GEERAERTS

Director

Also active at: HG IMMO

since 2010

GILLES SMITS

Director

Also active at: Wavrienne de Gestion Immobilière, PHARMA PROJECT, HG IMMO, Pharmacie Smits Basse Wavre, PHARMACIE SMITS

since 2010

Establishments

Establishment units

Physical locations of this company

Registered office

Avenue des Fauvettes 23

1341 Ottignies-Louvain-la-Neuve

2.196.574.403

Quai du Trompette 33 box 7

1300 Wavre

Active since 28 December 2010

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

HG IMMO same network

€ 64,635 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0832.287.120

VAT number

BE 0832.287.120

Registered office

Avenue des Fauvettes 23, 1341 Ottignies-Louvain-la-Neuve

Names & denominations

HG Pharma

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

28 December 2010

Peppol

Active · Active since 27 Nov 2025

Activities · NACE

Activiteiten van holdings

Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies

Holdings

Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering

Detailhandel in farmaceutische producten

Verhuur en exploitatie van eigen of geleased niet-residentieel onroerend goed, exclusief terreinen

Overige financiële dienstverlening, neg

View on CBE Public ↗ Annual accounts (NBB) ↗

HG Pharma

Financials

What happened to HG Pharma?

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions